An early assessment of the efficacy of medicines in the treatment of patients with COVID-19

Coronavirus infection 2019 is considered a modern challenge to the world community. In the absence of vaccines and antivirals, effective and safe medicines are an urgent request from the healthcare system. We have evaluated the medical technologies for COVID-19 which are being examined. The search w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	A. S. Kolbin
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2020
Materias:	coronavirus infection covid-19 clinical trials chloroquine hydroxychloroquine remdesivir lopinavir/ritonavir monoclonal antibodies Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/01eb08e21d814ff0b0dfa1aee6ed1e0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01eb08e21d814ff0b0dfa1aee6ed1e0c
record_format	dspace
spelling	oai:doaj.org-article:01eb08e21d814ff0b0dfa1aee6ed1e0c2021-11-22T07:09:54ZAn early assessment of the efficacy of medicines in the treatment of patients with COVID-192220-76192313-739810.15789/2220-7619-AEA-1458https://doaj.org/article/01eb08e21d814ff0b0dfa1aee6ed1e0c2020-05-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1458https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Coronavirus infection 2019 is considered a modern challenge to the world community. In the absence of vaccines and antivirals, effective and safe medicines are an urgent request from the healthcare system. We have evaluated the medical technologies for COVID-19 which are being examined. The search was conducted on the СlinicalTrials.gov at the beginning of April 2020. As a result it was shown that the growth of new clinical trials in the world devoted to COVID-19 is growing by 65% per week. More often, interventional clinical trials of the II and III phases are carried out. Most studies are planned or conducted in Western Europe (n = 92), China (n = 79), and the United States (n = 51). Surrogate points are usually evaluated, such as: clinical recovery, symptom-based disease relief (fever, cough, diarrhea, myalgia, shortness of breath), lack of progression of shortness of breath, rate of artificial ventilation, rate of admission to the intensive care unit, etc. It is antimalarial drugs that are mainly studied. Currently, it is not possible to discuss the efficacy and safety of a drug in the treatment of COVID-19, as most studies have just begun. The therapeutic regimens proposed now in clinical recommendations have no evidence base, and the studies indicated in them are at best considered hypothesizing.A. S. KolbinSankt-Peterburg : NIIÈM imeni Pasteraarticlecoronavirus infectioncovid-19clinical trialschloroquinehydroxychloroquineremdesivirlopinavir/ritonavirmonoclonal antibodiesInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 10, Iss 2, Pp 277-286 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	coronavirus infection covid-19 clinical trials chloroquine hydroxychloroquine remdesivir lopinavir/ritonavir monoclonal antibodies Infectious and parasitic diseases RC109-216
spellingShingle	coronavirus infection covid-19 clinical trials chloroquine hydroxychloroquine remdesivir lopinavir/ritonavir monoclonal antibodies Infectious and parasitic diseases RC109-216 A. S. Kolbin An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
description	Coronavirus infection 2019 is considered a modern challenge to the world community. In the absence of vaccines and antivirals, effective and safe medicines are an urgent request from the healthcare system. We have evaluated the medical technologies for COVID-19 which are being examined. The search was conducted on the СlinicalTrials.gov at the beginning of April 2020. As a result it was shown that the growth of new clinical trials in the world devoted to COVID-19 is growing by 65% per week. More often, interventional clinical trials of the II and III phases are carried out. Most studies are planned or conducted in Western Europe (n = 92), China (n = 79), and the United States (n = 51). Surrogate points are usually evaluated, such as: clinical recovery, symptom-based disease relief (fever, cough, diarrhea, myalgia, shortness of breath), lack of progression of shortness of breath, rate of artificial ventilation, rate of admission to the intensive care unit, etc. It is antimalarial drugs that are mainly studied. Currently, it is not possible to discuss the efficacy and safety of a drug in the treatment of COVID-19, as most studies have just begun. The therapeutic regimens proposed now in clinical recommendations have no evidence base, and the studies indicated in them are at best considered hypothesizing.
format	article
author	A. S. Kolbin
author_facet	A. S. Kolbin
author_sort	A. S. Kolbin
title	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
title_short	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
title_full	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
title_fullStr	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
title_full_unstemmed	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
title_sort	early assessment of the efficacy of medicines in the treatment of patients with covid-19
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2020
url	https://doaj.org/article/01eb08e21d814ff0b0dfa1aee6ed1e0c
work_keys_str_mv	AT askolbin anearlyassessmentoftheefficacyofmedicinesinthetreatmentofpatientswithcovid19 AT askolbin earlyassessmentoftheefficacyofmedicinesinthetreatmentofpatientswithcovid19
_version_	1718417894714376192

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19

Ejemplares similares